|
Dec. 13, 2011 |
|
|
Dec. 17, 2018 |
|
|
jRCT2080221670 |
Phase I/II trial of YHI-1003 plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer |
|
Phase I/II trial of YHI-1003 plus Capecitabine |
Yakult Honsha Co., Ltd. |
||
TEL: +81-3-5550-8968, FAX: +81-3-3248-5502 |
||
| 50 | ||
Interventional |
||
open-label, multicenter trial |
||
1-2 |
||
(1)Patients with recurrent or metastatic colorectal cancer |
||
(1)Patients with uncontrolled intercurrent illness |
||
| 20age old over | ||
| No limit | ||
Both |
||
Refractory Advanced Colorectal Cancer |
||
investigational material(s) |
||
safety |
||
efficacy and pharmacokinetic profile |
||
| Yakult Honsha Co.,Ltd. | |
| JapicCTI-111712 | |